Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)

This study has been completed.
Bristol-Myers Squibb
Information provided by (Responsible Party):
M.D. Anderson Cancer Center Identifier:
First received: November 16, 2005
Last updated: March 7, 2017
Last verified: March 2017
The goal of this clinical research study is to learn if dasatinib can help to control myeloproliferative disorders. The safety and tolerability of dasatinib will also be studied.

Condition Intervention Phase
Acute Myeloid Leukemia
Myelodysplastic Syndromes
Agnogenic Myeloid Metaplasia
Hypereosinophilic Syndrome
Polycythemia Vera
Leukemia, Myelomonocytic, Chronic
Drug: Dasatinib (BMS-354825)
Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: Therapy of Myeloid Metaplasia-Myelofibrosis, Atypical Chronic Myeloid or Myelomonocytic Leukemia, C-Kit Positive Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (AML-MDS), Hypereosinophilic Syndrome, Polycythemia Vera, and Mastocytosis With Dasatinib (BMS-354825)

Resource links provided by NLM:

Further study details as provided by M.D. Anderson Cancer Center:

Primary Outcome Measures:
  • Participant Response Rate [ Time Frame: Baseline to completion of 4 week cycle or until disease progression ]
    Response Rate is complete response plus partial response (CR+PR) for each disease category.

Secondary Outcome Measures:
  • Duration of Response (Survival) [ Time Frame: Baseline, once a week for a month, thereafter monthly ]
    Response duration is from date of first response until relapse. Survival is from start of therapy. They will be done using the Kaplan-Meier estimators, the log-rank tests and the Cox-proportional hazards models.

Enrollment: 68
Actual Study Start Date: November 15, 2005
Study Completion Date: March 3, 2017
Primary Completion Date: March 3, 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Dasatinib
Dasatinib 70 mg orally twice daily.
Drug: Dasatinib (BMS-354825)
70 mg orally twice daily
Other Name: Sprycel

Detailed Description:

Dasatinib is an experimental anti-cancer drug that is designed to block the function of BCR-ABL, which is the abnormal protein responsible for causing leukemia in some cells.

If you are found to be eligible to take part in this study, you will take dasatinib by mouth twice a day. If you have mastocytosis, you will take dasatinib by mouth once a day. A treatment cycle will be defined as 4 weeks (28 days) + 7 days. You will be instructed to take dasatinib in the morning (between about 6:00 a.m.-10:00 a.m.) and in the evening (between about 6:00 p.m.-10:00 p.m.).

Blood tests (about 2 - 3 teaspoons) will be done once a week for a month, then once a month for 5 years, then once every 6 months (if your doctor thinks it is needed) for the remainder of your treatment on this study. A bone marrow biopsy will be done after 1-2 months of therapy to document response.

Dasatinib will be given for as long as you are responding. You will be taken off study if the disease gets worse or intolerable side effects occur.

This is an investigational study. Dasatinib is authorized for use in research only. A total of 145 patients will take part in this study. All will be treated at MD Anderson.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patients >/= 18 years old who meet the following eligibility criteria
  2. Patients must have one of the following hematopoietic malignancies: C-kit positive (10% or more BM or PB MNC positive by flow) acute myeloid leukemia (AML excluding acute promyelocytic leukemia) or myelodysplastic syndrome (MDS) of the following types: Refractory-relapse AML-MDS including those who fail to achieve CR after the first cycle of induction; Second or subsequent AML-MDS refractory-relapse; Newly diagnosed AML-MDS patients over 60 years of age with karyotype other than t(15:17), inv16, t(8:21), who do not want chemotherapy.
  3. (Con't from # 2) Patients with MDS who do not want chemotherapy as initial treatment, or who are not eligible for the treatments of higher priority.
  4. Agnogenic myeloid metaplasia - myelofibrosis (MMM)
  5. Hypereosinophilic syndrome (HES)
  6. Polycythemia vera (PV)
  7. Mastocytosis
  8. Serum bilirubin less than 2mg%, serum creatinine less than 2mg% unless abnormality is considered due to hematologic malignancy by investigator.
  9. Eastern Cooperative Oncology Group (ECOG) Performance Status < 3
  10. Patients must sign an informed consent indicating they are aware of the investigational nature of this study, in keeping with the policies of the hospital.
  11. Women of pregnancy potential must practice an effective method of birth control during the course of the study, in a manner such that risk of failure is minimized. Prior to study enrollment, women of childbearing potential (WOCBP) (defined as not post-menopausal for 12 months or no previous surgical sterilization) must be advised of the importance of avoiding pregnancy during trial participation and the potential risk factors for an unintentional pregnancy.
  12. Continued from #11: In addition, men enrolled on this study should understand the risks to any sexual partner of childbearing potential and should practice an effective method of birth control.Women and men must continue birth control for the duration of the trial and at least 3 months after the last dose of study drug.
  13. Inclusion of women and minorities: As per NIH policy, women and members of minorities will be included in this protocol as they are referred in the relevant populations. There are no exclusions of women or minorities based on the study objectives.
  14. New York Heart Association (NYHA) Class < 3
  15. Ph negative MPD including chronic myelomonocytic leukemia (CMML).

Exclusion Criteria:

  1. Pregnant or breast-feeding women are excluded.
  2. All WOCBP MUST have a negative pregnancy test prior to first receiving investigational product. If the pregnancy test is positive, the patient must not receive investigational product and must not be enrolled in the study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00255346

United States, Texas
The University of Texas M.D. Anderson Cancer Center
Houston, Texas, United States, 77030
Sponsors and Collaborators
M.D. Anderson Cancer Center
Bristol-Myers Squibb
Principal Investigator: Hagop M Kantarjian, MD M.D. Anderson Cancer Center
  More Information

Additional Information:
Responsible Party: M.D. Anderson Cancer Center Identifier: NCT00255346     History of Changes
Other Study ID Numbers: 2004-0817
NCI-2012-01353 ( Registry Identifier: NCI CTRP )
Study First Received: November 16, 2005
Last Updated: March 7, 2017

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by M.D. Anderson Cancer Center:
targeted therapy
Acute myeloid leukemia (AML)
Myelodysplastic syndrome (MDS)
Agnogenic myeloid metaplasia - myelofibrosis (MMM)
Hypereosinophilic syndrome (HES)
Polycythemia vera (PV)

Additional relevant MeSH terms:
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Myelodysplastic Syndromes
Primary Myelofibrosis
Polycythemia Vera
Myeloproliferative Disorders
Hypereosinophilic Syndrome
Leukemia, Myelomonocytic, Chronic
Pathologic Processes
Neoplasms by Histologic Type
Bone Marrow Diseases
Hematologic Diseases
Precancerous Conditions
Leukocyte Disorders
Neoplasms, Connective Tissue
Neoplasms, Connective and Soft Tissue
Skin Diseases
Myelodysplastic-Myeloproliferative Diseases
Antineoplastic Agents
Protein Kinase Inhibitors processed this record on April 21, 2017